Literature DB >> 4119162

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy.

L M Lichtenstein, K Ishizaka, P S Norman, A K Sobotka, B M Hill.   

Abstract

Specific IgE anti-ragweed antibodies (IgEAR) were measured over two years in two groups of highly sensitive patients treated (immunized) with either ragweed extract or placebo and in a third group of placebo-treated, relatively insensitive patients. The IgEAR on the patients' basophils were assessed by ragweed antigen E (AgE)-induced histamine release; blocking (IgG) antibodies were measured by their ability to inhibit AgE induced histamine release. These data were evaluated against the clinical severity of ragweed hay fever in each patient. WE FOUND THAT: (a) In placebo treated patients IgEAR usually declined gradually prior to the ragweed season and were boosted by environmental exposure to ragweed pollen. (b) In immunized patients the IgEAR rose at the beginning of treatment, but fell as immunotherapy proceeded; by the end of the second year the levels had decreased in 18/19 patients. (c) The increase in blocking antibody during immunotherapy correlated significantly (P < 0.05) with the decrease in serum IgEAR. (d) Judged by their sensitivity to AgE induced histamine release, IgEAR on basophils correlated significantly with IgEAR in the serum of untreated patients (P < 0.01). (e) The highly sensitive placebo treated patients' symptom scores were significantly correlated with their IgEAR in serum (P < 0.01) and with the sensitivity of their basophils to AgE-induced histamine release (P < 0.01). Neither correlation was observed in the relatively insensitive patients. (f) In the treated group the IgEAR measurements predicted neither the degree of their illness nor their clinical improvement We conclude tha IgE antibody measurements may be useful in the assessment of the severity of reaginic allergy in highly sensitive patients. Its use in modestly sensitive patients requires patients requires further study, as does the inverse association between IgE and IgG antiragweed antibodies.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4119162      PMCID: PMC302277          DOI: 10.1172/JCI107204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization.

Authors:  L M Lichtenstein; P S Norman; W L Winkenwerder; A G Osler
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

2.  Histamine release from leukocytes of hypersensitive individuals. II. Reduced sensitivity of leukocytes after injection therapy.

Authors:  J J Pruzansky; R Patterson
Journal:  J Allergy       Date:  1967-01

3.  Antigenic structure of gamma-E-globulin and reaginic antibody.

Authors:  K Ishizaka; T Ishizaka; W D Terry
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

4.  Trials of alum-precipitated pollen extracts in the treatment of hay fever.

Authors:  P S Norman; W L Winkenwerder; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1972-07       Impact factor: 10.793

5.  Measurement of IgE in normal and allergic serum by radioimmunoassay.

Authors:  G J Gleich; A K Averbeck; H A Swedlund
Journal:  J Lab Clin Med       Date:  1971-04

6.  A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies.

Authors:  L M Lichtenstein; P S Norman; W L Winkenwerder
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

7.  A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody.

Authors:  L M Lichtenstein; N A Holtzman; L S Burnett
Journal:  J Immunol       Date:  1968-08       Impact factor: 5.422

8.  Immunoglobulin levels in Ethiopian preschool children with special reference to high concentrations of immunoglobulin E (IgND).

Authors:  S G Johansson; T Mellbin; B Vahlquist
Journal:  Lancet       Date:  1968-05-25       Impact factor: 79.321

9.  In vitro diagnosis of atopic allergy. 3. Quantitative estimation of circulating IgE antibodies by the radioallergosorbent test.

Authors:  S G Johansson; H Bennich; T Berg
Journal:  Int Arch Allergy Appl Immunol       Date:  1971

10.  Chemical coupling of proteins to agarose.

Authors:  J Porath; R Axen; S Ernback
Journal:  Nature       Date:  1967-09-30       Impact factor: 49.962

View more
  31 in total

Review 1.  Assessing basophil functional measures during monoclonal anti-IgE therapy.

Authors:  Sarbjit S Saini; Donald W MacGlashan
Journal:  J Immunol Methods       Date:  2012-06-01       Impact factor: 2.303

Review 2.  Allergen injection immunotherapy for seasonal allergic rhinitis.

Authors:  M A Calderon; B Alves; M Jacobson; B Hurwitz; A Sheikh; S Durham
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Quantitative relationships between IgE antibody and blocking antibodies specific for antigen E in patients given immunotherapy with ragweed antigen E.

Authors:  C R Zeiss; W J Metzger; D Levitz
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

4.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Authors:  J Corne; R Djukanovic; L Thomas; J Warner; L Botta; B Grandordy; D Gygax; C Heusser; F Patalano; W Richardson; E Kilchherr; T Staehelin; F Davis; W Gordon; L Sun; R Liou; G Wang; T W Chang; S Holgate
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  The rationale for immunotherapy in respiratory allergies.

Authors:  P S Norman
Journal:  Trans Am Clin Climatol Assoc       Date:  1978

6.  Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes.

Authors:  J J Machiels; M A Somville; P M Lebrun; S J Lebecque; M G Jacquemin; J M Saint-Remy
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 7.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 8.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

9.  IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release.

Authors:  T A Platts-Mills; R K von Maur; K Ishizaka; P S Norman; L M Lichtenstein
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

10.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.